Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Employee Benefit Plans

Employee Benefit Plans	9 Months Ended
Sep. 30, 2021
Employee Benefit Plans
Employee Benefit Plans	11. Employee Benefit Plans The Company has an employee benefit plan for its United States-based employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the employee contribution up to a defined maximum. The Company made no matching contribution for each of the three and nine months ended September 30, 2021 and 2020. As a result of the 401(k) plan compliance review for the year ended December 31, 2020, the Company contributed $25,905 to eligible participants during the third quarter of 2021. As of September 30, 2021, the Company has accrued an additional estimate of $15,251 for contributions likely due as a result of the 401(k) plan compliance review to be performed for the year ended December 31, 2021.

Employee Benefit Plans

9 Months Ended

Sep. 30, 2021

11. Employee Benefit Plans

The Company has an employee benefit plan for its United States-based employees under Section 401(k) of the Internal Revenue Code. The Plan allows all eligible employees to make contributions up to a specified percentage of their compensation. Under the Plan, the Company may, but is not obligated to, match a portion of the employee contribution up to a defined maximum. The Company made no matching contribution for each of the three and nine months ended September 30, 2021 and 2020.

As a result of the 401(k) plan compliance review for the year ended December 31, 2020, the Company contributed $25,905 to eligible participants during the third quarter of 2021. As of September 30, 2021, the Company has accrued an additional estimate of $15,251 for contributions likely due as a result of the 401(k) plan compliance review to be performed for the year ended December 31, 2021.